Application Note
VEGF Alternative (VEGFR2 agonist) Peptide [PG-007]
14days Stability in Cell Culture Medium at 37℃
Vascular endothelial growth factor (VEGF) is an essential growth cytokine for endothelial
cells, and not only functions as a cell mitogen, but also promotes cell migration, survival,
angiogenesis and vasculogenic process. It promotes lumen formation and increases vascularpermeability [1]. VEGF is known to have a series of its related molecules (collectively
designated as VEGF family), all of which form dimers and bind to one or more of 3 types ofreceptor tyrosine kinases (VEGFR1, 2 and 3) [2]. These dimeric forms of VEGFs have beenshown to modulate cellular functions by inducing receptor dimerization,
autophosphorylation, and intracellular signaling upon binding to these receptors [3].
The N-terminal region of VEGF binds to each of the receptors listed above, but when stored
under neutral pH conditions, some amino acid residues in this domain may be modified, suchas deamidation or oxidation, possibly causing self-degradation [4]. Therefore, for a long-time
culture, the culture should be replaced with fresh medium frequently depending on the used
cells type and experimental conditions.
All the growth factor alternative peptides from Peptirowth have unique cyclic structure
understood to be structurally stable and are expected to be stable in the cell culture media[5]. At this testing, time-dependent changes of VEGF alternative peptide "PG-007"
concentrations in a liquid medium under standard cell culture conditions (at 37°C) were
determined, demonstrating the PG-007 concentration was apparently maintained as over
80% even after 2 weeks (see below).

⚫

Method: PG-007 (final concentration: 100 nM) was added into the liquid medium (commerciallyavailable DMEM/F-12) and maintained at 37°C for 14 days. Relative concentrations of PG-007
were measured by LC/MS system at several points (at 0, 1, 3, 7, and 14 days).

⚫

Result: Concentrations were shown as maintained at 80% or higher even after 14 days undernormal cell culture conditions (N=3, mean ± SD, in the upper graph).
1

Application Note⚫

References：1) Ribatti D. Mech Dev. 2019; 160: 103579.
2) Shibuya M. Endothelium. 2006; 13: 63-69.
3) Shibuya M. Cold Spring Harb Perspect Biol. 2013; 5: a009092.
4) Goolcharran C, et al. AAPS PharmSci. 2000; 2: E5.
5) Nature Portfolio 2022. A growing market for synthetically produced peptides (nature.com)⚫

Precautions regarding the product：➢Please read the Safety Data Sheet (SDS) carefully prior to use the product.

➢To use this product immediately after dissolving is recommended.

➢This product is a reagent for research use only. Not to use for any purpose other thanresearch or investigational use.

➢Specifications, contents, appearances, etc. of this product may be changed without notice.

➢Contact us or our sales agents, if with any large amounts or other special specification

Product lineup
Product code

Factor Name

PG-001

HGF alternative peptide

PG-002

TGFβ1 inhibitor

PG-003

BDNF alternative peptide

PG-004

Noggin-like peptide

PG-005

BMP7 selective inhibitor

PG-006

BMP4 selective inhibitor

PG-007

VEGF alternative peptide

PG-008Wnt3a alternative peptide

PG-009Synthetic EGF (human)

PG-010

TPO alternative peptide《Contact regarding PeptiGrowth’s products and application notes》
Contact in North America

MIFI Bioceuticals

Contact in the EU/UK

IVICT Europe GmbH

Hackensack, NJ, USA

Duesseldorf, GERMANY

TEL: 201-242-5104

TEL: +49-(0)172-204-4403

E-mail: PG@mifibioceuticals.com

E-mail: koji.okada@ivic-t.com

PeptiGrowth Inc. Tokyo, JAPAN, TEL : +81-(0)70-4503-1497, E-mail : contact@peptigrowth.com

2